Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
NCT ID: NCT00085891
Last Updated: 2009-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
535 participants
INTERVENTIONAL
2004-06-30
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
NCT00090324
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
NCT00206115
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
NCT00083954
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
NCT00321490
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
NCT00326144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine Fumarate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a documented clinical diagnosis of schizophrenia
* Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria
* Patients with a known lack of response to previous treatment with quetiapine
* Patients who have participated in another drug study within 4 weeks prior to enrollment into this study
* Patients who have previously participated in this study or study D1444C00132
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Seroquel Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Cerritos, California, United States
Los Angeles, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Ana, California, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Miami, Florida, United States
Oak Brook, Illinois, United States
Research Site
Oakbrook Terrace, Illinois, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Rockville, Maryland, United States
Brighton, Massachusetts, United States
Research Site
Jackson, Mississippi, United States
Research Site
St Louis, Missouri, United States
Research Site
Holliswood, New York, United States
Research Site
Lawrence, New York, United States
Research Site
Staten Island, New York, United States
Research Site
Medina, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Norristown, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Sioux Falls, South Dakota, United States
Research Site
Memphis, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Irving, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Kirkland, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1444C00133
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.